Investor Relations

NEW YORK , Aug. 31, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated

Novel stromal-CAR-iNKT shows activity in solid tumors; FIH planned for 2023 Clinical presentation of AgenT-797 in solid tumors, myeloma, and ARDS planned for 2H2022 Under the leadership team of Dr. Joy Zhou , completed internal cGMP production of AgenT-797 with expansion capacity to treat >700,000

NEW YORK , Aug. 02, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated